10.

Stockholder’s Equity

In February 2021, the Company sold shares of its common stock in two separate transactions: On February 3, 2021, 15,300,000 shares were sold at $0.70 for gross proceeds of $10,710,000; and on February 18, 2021, 10,990,000 shares were sold at $1.30 for gross proceeds of $14,287,000. A total of $1,654,820 of cash issuance costs were incurred on these sales.

At June 30, 2021 and December 31, 2020, the Company accrued $166,250 and $110,000, respectively, in directors’ fees payable that will be paid in common stock.

During the three month period ended June 30, 2021, the Company issued 41,667 shares of common stock and received $27,084 in cash from the exercise of warrants; no warrants were exercised during the three month period ended June 30, 2020.

During the six-month period ended June 30, 2021, the Company issued 3,765,477 shares of common stock and received $1,790,703 in cash from the exercise of warrants. For the same period in 2020, the Company issued 250,000 shares of common stock in satisfaction of related party debt of $62,500 from the exercise of warrants.

Warrants

Concurrent with the February 3, 2021 sale of common stock, the Company sold warrants to purchase 7,650,000 shares of common stock at an exercise price of $0.85 per share. The warrants are initially exercisable six months following issuance and expire five and one-half years from the issuance date. In connection with the February 2021 sales of common stock, the Company also issued 1,606,500 warrants with an exercise price of $0.85 and 804,000 warrants with an exercise price of $0.46 as commission to the placement agent. These warrants expire in early 2026.

Transactions in common stock purchase warrants for the six month period ended June 30, 2021 and the year ended December 31, 2020 are as follows: